Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With Diffuse Large B-Cell and Follicular Lymphoma

Study Identifier
P24-903
CT.gov Identifier
NCT06830759
EudraCT Identifier
Not available
EUCTIS ID
Not available
For general inquiries, please contact

844-663-3742 or [email protected]

Recruiting
Sign up for trial alerts

Study Details

Medical Condition
  • Blood Cancer - Diffuse Large B-Cell Lymphoma (DLBCL)
  • Blood Cancer - Follicular Lymphoma (FL)
    • Study Drug
    N/A
    Phase
    N/A
    Sex
    Female & Male
    Age
    18+ years
    Inclusion and Exclusion Criteria
    Inclusion Criteria:
    * Participants who are scheduled to be treated with epcoritamab for Treatment after two or more prior lines of therapy 3L+ diffuse large B-cell lymphoma ((D)LBCL) or 3L+ Follicular lymphoma (FL). * Treatment with epcoritamab should be administered in accordance with the approved local label in the participating country. * The decision to treat the participant should have been made by the clinician prior to, and independently of any decision to approach the participant to participate in this study.
    Exclusion Criteria:
    * Any condition included in the contraindications section of the approved local epcoritamab label in the participating country. * Participation in a concurrent interventional clinical trial (not including non-interventional/ observational study, PMOS, or registry participation) from enrollment and throughout the study.

    Protocol Summary

    Diffuse large B-cell lymphoma (DLBCL) is an aggressive and rare cancer of a type of immune cells (a white blood cell responsible for fighting infections) and the most common type of non-Hodgkin lymphoma. Follicular Lymphoma (FL) is a slow-growing type of non-Hodgkin lymphoma. The purpose of this study is to assess the real-world effectiveness of subcutaneous epcoritamab in adult participants with advanced DLBCL and FL.

    Epcoritamab is an investigational drug being developed for treating participants with DLBCL and FL. Approximately 700 participants will be enrolled in approximately 80 sites across 12-20 countries globally.

    Participants will receive epcoritamab as prescribed by their physician in accordance with local country label. Participants will be followed for up to 3 years.

    There is expected to be no additional burden for participants in this trial. Participants will attend regular visits during the study at a hospital or clinic according to their routine clinical practice.

    Study Locations

    Location
    Status
    Location
    Hospital Britanico de Buenos Aires /ID# 274419
    Ciudad Autonoma de Buenos Aire, Buenos Aires, Argentina, 1280
    Status
    Recruiting
    Location
    Hospital Universitario Austral /ID# 274393
    Pilar, Buenos Aires, Argentina, 1629
    Status
    Recruiting
    Location
    Instituto Alexander Fleming /ID# 277284
    Ciudad Autonoma de Buenos Aire, Buenos Aires F.D., Argentina, 1426
    Status
    Recruiting
    Location
    Hospital Privado Universitario De Córdoba /ID# 274457
    Córdoba, Córdoba Province, Argentina, 5016
    Status
    Recruiting
    Location
    Hospital Italiano de Buenos Aires /ID# 274418
    Buenos Aires, Argentina, 1181
    Status
    Recruiting
    Location
    Fundacion Argentina contra la Leucemia (FUNDALEU) /ID# 274390
    Buenos Aires, Argentina, 1227
    Status
    Recruiting
    Showing {first} - {last} of {total} Results